Exendin 9 - Eiger BioPharmaceuticals

Drug Profile

Exendin 9 - Eiger BioPharmaceuticals

Alternative Names: Exendin (9-39); Exendin 9-39

Latest Information Update: 21 Jan 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer Eiger BioPharmaceuticals, Inc.; Stanford University
  • Class Peptide fragments
  • Mechanism of Action Glucagon-like peptide-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypoglycaemia

Most Recent Events

  • 12 Dec 2016 Exendin 9 - Eiger BioPharmaceuticals receives Orphan Drug status for Hyperinsulinaemic Hypoglycaemia in USA
  • 12 Dec 2016 Interim adverse events and efficacy data from a phase II trial in Hypoglycaemia released by Eiger Biopharmaceuticals
  • 12 Dec 2016 Eiger Biopharmaceuticals plans a phase I PK study for Hypoglycaemia in Q1 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top